The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The myeloma trial portfolio in the UK: data in high-risk disease and smoldering myeloma
In this video, Sarah Gooding, MD, PhD, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, comments on the United Kingdom’s strong history of investigator-led studies in multiple myeloma (MM), highlighting the country’s exciting trial portfolio at different stages in the disease course. Additionally, Dr Gooding encourages clinicians to leverage translational science to improve precision patient care and diagnostics. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In the UK, I think we have a really strong history of investigator-led studies. We have done fantastic, large studies in newly diagnosed myeloma in the past, like Myeloma XI and trials leading on from that. At the moment, we have the RADAR trial, which will finish recruitment this year, 1,400 newly diagnosed myeloma patients.
And what I think in the UK we’re really good at is the translational research that accompanies these trials that helps us understand more about how high-risk disease behaves and about how we could intensify treatment in high-risk disease...
In the UK, I think we have a really strong history of investigator-led studies. We have done fantastic, large studies in newly diagnosed myeloma in the past, like Myeloma XI and trials leading on from that. At the moment, we have the RADAR trial, which will finish recruitment this year, 1,400 newly diagnosed myeloma patients.
And what I think in the UK we’re really good at is the translational research that accompanies these trials that helps us understand more about how high-risk disease behaves and about how we could intensify treatment in high-risk disease. For example, thinking about the OPTIMUM trial that looked at that so beautifully.
But the other thing that in the UK, I think we have some really interesting data coming out will be around smoldering myeloma. So we have a lot of translational research in the smoldering myeloma space in the UK at the moment. And we have some interventional trials in smoldering myeloma open due to start this year. So we have a very exciting trial portfolio at the different disease stages in myeloma. And I think as clinicians in the field, we should be taking advantage of these trials and in particular working to understand how we can use the translational science around that to improve our precision patient care and our precision diagnostics that we can roll out.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
